Feedback

WHO approves India's Covaxin vaccine for emergency use

Source : 112 Ukraine

According to the WHO, the benefits far outweighed the risks
18:55, 3 November 2021

Open source

The World Health Organization (WHO) has granted approval for emergency authorization to Covaxin vaccine co-developed by India’s medical-research agency and local manufacturer Bharat Biotech International Ltd, the WHO said in a tweet.

The vaccine was approved in India in January while the third phase of clinical trials was still under way, sparking some concern and criticism.

Related: Only vaccinated, holders of negative PCR tests or Covid certificates to be allowed in Parliament building

Bharat Biotech, which makes the vaccine, has since published data suggesting 78% efficacy.

The WHO's expert panel, which authorises emergency approvals, had asked for more data last month while examining the application Bharat Biotech had filed in July.

In its approval it said:

  • The vaccine was recommended for use in two doses, with a dose interval of four weeks, in all age groups 18 and above
  • Covaxin had 78% efficacy against Covid 19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements
  • Available data on vaccination of pregnant women with the vaccine are insufficient to assess vaccine safety or efficacy in pregnancy 
Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more